# Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

> **NCT05039658** · PHASE1 · UNKNOWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** IBI110 plus sintilimab
- **DRUG:** IBI110

## Key facts

- **NCT ID:** NCT05039658
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-27
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-12-02
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05039658

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05039658, "Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05039658. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*